Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

類似資料

• Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
  著者:: Liu, Xiaochun, 等
  出版事項: (2016)
• Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors
  著者:: Mita, Monica, 等
  出版事項: (2017)
• Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
  著者:: Wheler, Jennifer J., 等
  出版事項: (2014)
• PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials
  著者:: Janku, Filip, 等
  出版事項: (2012)
• PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
  著者:: Janku, Filip, 等
  出版事項: (2012)